| AEFI |
Adverse event following immunization |
|
| AFP |
Acute flaccid paralysis |
|
| aVDPV |
Ambiguous vaccine-derived poliovirus |
|
| BMGF |
Bill & Melinda Gates Foundation |
|
| bOPV |
Bivalent oral polio vaccine |
|
| C4D |
Communication for development |
|
| CDC |
US Centers for Disease Control and Prevention |
|
| cVDPV (and cVDPV1, cVDPV2, cVDPV3) |
Circulating vaccine-derived poliovirus, or variant poliovirus (type 1, type 2, type 3) |
|
| DTP3 |
Diphtheria–tetanus–pertussis vaccine third dose |
|
| EI |
Essential immunization |
|
| EMG |
Eradication Management Group |
|
| EPI |
Expanded Programme on Immunization |
|
| ES |
Environmental surveillance |
|
| EUL |
(WHO) Emergency Use Listing |
|
| FATA |
Federally Administered Tribal Areas (Pakistan) |
|
| fIPV |
Fractional-dose inactivated polio vaccine |
|
| FOMWAN |
Federation of Muslim Women’s Associations in Nigeria |
|
| FRR |
Financial Resource Requirements |
|
| FWG |
Finance Working Group |
|
| GAPIII |
Third edition of the Global Action Plan to minimize post-eradication poliovirus facility-associated risk |
|
| GCC |
Global Commission for Certification of the Eradication of Poliomyelitis |
|
| GIS |
Geographic information system |
|
| GPEI |
Global Polio Eradication Initiative |
|
| GPS |
Global positioning systems device |
|
| GPLN |
Global Polio Laboratory Network |
|
| GVAP |
Global Vaccine Action Plan |
|
| ICC |
Interagency Coordinating Committee |
|
| IFFIm |
Innovative Financing Facility for Immunization |
|
| IMB |
Independent Monitoring Board |
|
| IMG |
Immunization Systems Management Group |
|
| IPV |
Inactivated polio vaccine |
|
| IVD |
Immunization and Vaccine Development |
|
| iVDPV |
Immunodeficiency-associated vaccine-derived poliovirus |
|
| LGA |
Local Government Area |
|
| LQAS |
Lot Quality Assurance Sampling |
|
| mOPV |
Monovalent oral polio vaccine |
|
| NCC |
National Certification Committee |
|
| NEAP |
National Emergency Action Plan |
|
| NGO |
Non-governmental organization |
|
| NID |
National Immunization Day |
|
| nOPV (nOPV1, nOPV2, nOPV3) |
Novel oral polio vaccine (type 1, type 2, type 3) |
|
| NSTOP |
Nigeria Stop Transmission of Polio programme |
|
| OPV |
Oral polio vaccine |
|
| PAG |
Political Advocacy Group |
|
| PHEIC |
Public Health Emergency of International Concern |
|
| POB |
Polio Oversight Board |
|
| PPG |
Polio Partners Group |
|
| PQ |
(WHO) pre-qualification |
|
| PRC |
Polio Research Committee |
|
| PSC |
Polio Steering Committee |
|
| RCC |
Regional Certification Commission |
|
| RED |
Reaching Every District |
|
| SAGE |
Strategic Advisory Group of Experts on Immunization |
|
| SIA |
Supplementary immunization activity |
|
| SIAD |
Short Interval Additional Dose |
|
| SNID |
Subnational Immunization Day |
|
| STOP |
Stop Transmission of Polio programme |
|
| TAG |
Technical Advisory Group |
|
| tOPV |
Trivalent oral polio vaccine |
|
| UNICEF |
United Nations Children’s Fund |
|
| VAPP |
Vaccine-associated paralytic poliomyelitis |
|
| VDPV |
Vaccine-derived poliovirus |
|
| VfM |
Value for money |
|
| VPD |
Vaccine-preventable disease |
|
| WHA |
World Health Assembly |
|
| WHO |
World Health Organization |
|
| WPV (WPV1, WPV2, WPV3) |
Wild poliovirus (type 1, type 2, type 3) |
|
